Literature DB >> 30879541

Early Outcomes of Liver Transplantation Using Donors After Circulatory Death in Patients With Hepatocellular Carcinoma: A Comparative Study.

L A Martinez-Insfran1, P Ramirez2, P Cascales2, F Alconchel2, D Ferreras2, B Febrero2, M Martinez3, M R González4, F Sanchez-Bueno2, R Robles2, P Parrilla2.   

Abstract

INTRODUCTION: Donation after circulatory death (DCD) has increased in the last decade, although a slight increase in surgical complications has been reported in liver transplantation (LT). Therefore, DCD is not overall recommended because it entails an added risk. However, DCD in selected patients shows acceptable results.
OBJECTIVE: The objective was to analyze the characteristics, early outcomes, and survival at 1 year post-LT from a single institute (January 2015 to May 2017).
MATERIALS AND METHODS: We included 18 DCD-LTs and compared them with a control group of 18 donation after brain death (DBD) LTs. We analyzed pre- and posttransplant variables related to donors, recipients, and intraoperative early outcomes within patients transplanted due to hepatocellular carcinoma (HCC). A descriptive analysis, Mann-Whitney U test, χ2, or Fisher test was performed when appropriate, as well as multivariate analysis in case of statistical significance. A variable is considered as statistically significant when it reaches a value of P < .05.
RESULTS: In DBD, we found a lower length of stay in the intensive care unit before retrieval and a higher rate of alcoholism and diabetes mellitus, Model for End-Stage Liver Disease score, and Child B and C score (P < .05). Most of the DCD were originally from the same LT recipient center, and a higher donor mean post-LT alanine aminotransferase level was found (P < .05). Survival for the DBD group was 88% and 75% in the DCD group at 1 year post-LT, being not significant (NS).
CONCLUSION: HCC recipients who are transplanted with good quality DCD livers do no worse than those transplanted with livers from DBD donors, although a good selection of them is crucial.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30879541     DOI: 10.1016/j.transproceed.2018.10.021

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

Review 1.  Mitochondria and Cancer Recurrence after Liver Transplantation-What Is the Benefit of Machine Perfusion?

Authors:  Alessandro Parente; Mauricio Flores Carvalho; Janina Eden; Philipp Dutkowski; Andrea Schlegel
Journal:  Int J Mol Sci       Date:  2022-08-28       Impact factor: 6.208

Review 2.  Preventing Tumour Recurrence after Liver Transplantation: The Role of Machine Perfusion.

Authors:  Yuri Boteon; Mauricio Alfredo Flores Carvalho; Rebecca Panconesi; Paolo Muiesan; Andrea Schlegel
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

3.  Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.

Authors:  Jordyn Silverstein; Garrett Roll; Jennifer L Dodge; Joshua D Grab; Francis Y Yao; Neil Mehta
Journal:  Liver Transpl       Date:  2020-07-21       Impact factor: 5.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.